Printed on
L’Oréal has acquired a majority stake within the UK’s Medik8 because it seeks to develop its place within the skincare market, the French magnificence big confirmed on Monday.
As a part of the deal, personal fairness agency Inflexion will stay a minority shareholder, and the present administration committee may also keep of their roles.
The price of the stake is formally undisclosed, though the Monetary Instances reported final week that the potential deal was value round €1bn.
L’Oréal’s share value was roughly unchanged on the information.
“We’re delighted to welcome Medik8 to the L’Oréal household,” mentioned Cyril Chapuy, President of L’Oréal LUXE. “As a premium skincare vary, with excessive ranges of confirmed efficacy at an accessible value level, Medik8 completely enhances our present skincare portfolio,” he added.
L’Oréal has been searching for to capitalise on the increase in science-driven skincare, partly pushed by social media influencers.
Manufacturers already below its “Dermatological Magnificence Division” embody La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science.
This unit introduced in over €7bn in income in 2024, representing an virtually 10% year-on-year rise, making it L’Oréal’s fastest-growing division.
Searching for to develop its portfolio, L’Oréal purchased cleaning soap maker Aesop in 2023, and Korean magnificence model Dr.G in December.
Final 12 months, L’Oréal additionally acquired a ten% stake in skincare agency Galderma, in addition to buying the sweetness licence for Miu Miu.
On the time of the Galderma deal, the French agency mentioned it was “more and more investing in a extra holistic method, spanning your complete magnificence routine” — thereby “anticipating and intercepting the indicators of pores and skin ageing”.
Medik8, based in 2009, specialises in anti-ageing therapies and was purchased by UK-based personal fairness agency Inflexion in 2021.